30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Sanofi Reports 1Q19 Orthobiologic Revenue of €68MM, Flat vs. 1Q18 -


Sanofi’s hyaluronic acid product lines, Synvisc and Synvisc-One, posted revenue of USD $76.4.1MM in 1Q19, flat vs. 1Q18.

  • U.S. revenue loss diminished from 2018, -2.2% vs. 1Q18
  • Emerging markets were strong, with +15.4% revenue vs. last year


Synvisc and Synvisc-One sales on an as-reported basis are as follows ($MM).

  1Q19 1Q18 % Chg % Chg
Orthobiologics $76.4 $76.4 $0.0 0.0%

Synvisc and Synvisc-One sales by geographic region are as follows ($MM).

Geographic Region 1Q19 1Q18 % Chg % Chg
US $49.4 $50.6 -$1.1 -2.2%
Ex-US $27.0 $25.8 $1.1 4.3%
   Europe $6.7 $6.7 $0.0 0.0%
   Emerging Markets $16.9 $14.6 $2.2 15.4%
   Rest of World $3.4 $4.5 -$1.1 -25.0%
Total  $76.4 $76.4 $0.0 0.0%

Sources: Sanofi

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.